The emergence of embedded three‐dimensional (3D) bioprinting has revolutionized the biofabrication of free‐form constructs out of low‐viscosity and slow‐crosslinking hydrogels. Using gel‐based support baths has limitations including lack of proper oxygenation and nutrition and complications with bath removal. Herein, a novel‐embedded 3D bioprinting technique is developed with an albumin foam support bath as a promising substitute. The proposed technique, in‐foam bioprinting, offers excellent printability and convenience in bath removal while providing cells with easy access to oxygen and nutrients. The foam‐based support bath is characterized through foam stability and rheological tests. The bubble size in the foam is measured to study the change in the structure of the bath due to the coalescence of the bubbles over time. Free‐form structures are successfully 3D printed with thermoresponsive chitosan‐based bioinks to demonstrate the capability of the in‐foam bioprinting technique. The viability of bioprinted fibroblast L929 cells is studied over a seven‐day period, showing high cell viability of over 97%, which is attributed to the abundance of oxygen and nutrition in the foam support bath. Importantly, in‐foam bioprinting is beneficial for biofabricating large samples with a long printing time without jeopardizing cell viability.
Despite their recognized potential for ischemic tissue repair, the clinical use of human mesenchymal stromal cells (hMSC) is limited by the poor viability of cells after injection and the variability of their paracrine function. In this study, we show how the choice of biomaterial scaffolds and the addition of cell preconditioning treatment can address these limitations and establish a proof-of-concept for cryopreservable hMSC-loaded microbeads. Injectable microbeads in chitosan, chitosan–gelatin, and alginate were produced using stirred emulsification to obtain a similar volume moment mean diameter (D[4,3] ∼ 500 µm). Cell viability was determined through live/dead assays, and vascular endothelial growth factor (VEGF) release was measured by ELISA. Proangiogenic function was studied by measuring the wound closure velocity of human umbilical vein endothelial cells (HUVEC) co-cultured with MSC-loaded microbeads. The effect of freeze–thawing on microbeads morphology, porosity, injectability and encapsulated MSC was also studied. hMSC-loaded chitosan-based microbeads were found to release 11-fold more VEGF than alginate microbeads (p < 0.0001) and chitosan–gelatin was chosen for further studies because it presented the best cell viability. Preconditioning with celastrol significantly enhanced the viability (1.12-fold) and VEGF release (1.40-fold) of MSC-loaded in chitosan–gelatin microbeads, as well as their proangiogenic paracrine function (1.2-fold; p < 0.05). In addition, preconditioning significantly enhanced the viability of hMSC after 1 and 3 d in low-serum medium after cryopreservation (p < 0.05). Cryopreserved hMSC-loaded microbeads maintained their mechanical properties, were easily injectable through a 23G needle, and kept their paracrine function, enhancing the proliferation and migration of scratched HUVEC. This study shows the advantage of chitosan as a scaffold material and concludes that chitosan–gelatin microbeads with celastrol-preconditioned cells form a promising off-the-shelf, cryopreservable allogenic MSC product. In vivo testing is required to confirm their potential in treating ischemic diseases or other clinical applications.
Mesenchymal stromal/stem cells hold potential in repairing damaged tissue through paracrine effects. Their delivery though injectable biodegradable microbeads can improve cell retention and survival at the infusion site. A stirred emulsion process was previously implemented to immobilize these cells in injectable chitosan microbeads for cell therapy applications, but this process leads to broad bead size distribution (coefficient of variation > 40 %). Polydisperse beads may negatively affect the viability of the entrapped cells through oxygen limitations, damage to larger beads during injection, and reduced control over the cell payload and treatment reproducibility. The objective of this work was to modify a microchannel emulsification system initially designed for alginate-based encapsulation to immobilize mesenchymal stromal/stem cells in monodisperse chitosan microbeads. The main factors (e.g., microchannel geometry, chitosan solution viscosity, interfacial tension and flow rate) affecting droplet generation and diameter were investigated. The adapted process enabled the production of monodisperse chitosan microbeads with controlled sizes ranging from 600 µm – 1500 µm in diameter at a coefficient of variation less than 10 %. In a single pass through a 21 G syringe needle (ID: 513 µm), the fraction of ruptured beads was significantly reduced for microchannel-generated vs stirred emulsion-generated beads with matching volume-weighed bead diameter (D[4,3]). The viability of the immobilized cells immediately after the process was 95 % ± 2 % and no significant difference in cell survival and growth factor secretion was observed between microchannel and stirred emulsion-generated beads over 3 days of culture. Future directions include channel multiplexing to increase throughput for clinical applications. Although the device was developed for cell encapsulation, this process could be implemented for encapsulation of other biomolecules, bioactive or living cell agents for applications in the food and drug industry.
Embedded bioprinting enables the fabrication of complex, cell-laden structures by extruding bioinks into support baths. This technique has advanced the field of tissue engineering by expanding the range of printable bioinks and enabling the creation of intricate geometries; however, limitations such as instability and inadequate oxygen and nutrient delivery in current support materials restrict long print durations and compromise fidelity. Recently, albumin-based foams have been proposed as oxygen- and nutrient-permeable supports, but their rapid degradation restricts practical use. Here, we report the stabilization of albumin foams through the incorporation of pectin, a biocompatible polysaccharide. Three formulations—albumin-only (A8), albumin with 1% pectin (A8P1), and albumin with 2% pectin (A8P2)—were evaluated for foam stability, bubble morphology, rheology, and physicochemical properties. Pectin significantly delayed drainage and bubble coalescence while maintaining essential rheological features such as shear-thinning and recovery. These improvements enabled the embedded printing of chitosan, a low-viscosity and slow-crosslinking hydrogel, into multilayered and freeform structures with high fidelity. Cell viability assays confirmed that pectin did not compromise biocompatibility; A8P1 provided the most favorable microenvironment and outperformed conventional FRESH baths during extended incubation, owing to enhanced oxygen diffusion and a more physiological pH. Overall, pectin-stabilized albumin foams offer a simple, biocompatible, and self-removable support system that addresses key limitations of embedded bioprinting and broadens the range of printable bioinks.